Session 25 - CROI 2011

Home

Session 25-Oral Abstracts
Advances in PrEP
Tuesday, 10 am-12:15 pm; Auditorium

10:00 am 92	Pre-exposure Chemprophylaxis for Prevention of HIV among Trans-women and MSM: iPREx Study Robert Grant*¹, J Lama², D Glidden³, and iPrEx Study Team ¹Gladstone Inst of Virology and Immunology, San Francisco, CA, US; ²Investigaciones Medicas en Salud, Lima, Peru; and ³Univ of California, San Francisco, US
10:30 am 93	BMD Loss in HIV^– Men Participating in a TDF PrEP Clinical Trial in San Francisco Albert Liu*^1,2, E Vittinghoff², R Irby², K Mulligan², D Sellmeyer³, K Mayer⁴, M Thompson⁵, R Gvetadze⁶, L Grohskopf⁷, and S Buchbinder^1,2 ¹San Francisco Dept of Publ Hlth, CA, US; ²Univ of California, San Francisco, US; ³Johns Hopkins Univ Sch of Med, Baltimore, MD, US; ⁴Fenway Hlth, Boston, MA, US; ⁵AIDS Res Consortium of Atlanta, GA, US; ⁶Northrop Grumman, Atlanta, GA, US; and ⁷CDC, Atlanta, GA, US
10:45 am 94LB	Effects of FTC/TDF on Bone Mineral Density in Seronegative Men from 4 Continents: DEXA Results of the Global iPrEx Study Kathleen Mulligan*¹, D Glidden¹, P Gonzales², M-E Ramirez-Cardich³, A Liu^1,4, S Namwongprom⁵, P Chodacki⁶, L Mendonça⁷, V McMahan⁸, R Grant^1,8, and iPrEx Study Team ¹Univ of California, San Francisco, US; ²Investigaciones Medicas en Salud, Lima, Peru; ³Assn Civil Impacta Salud y Ed, Lima, Peru; ⁴San Francisco Dept of Publ Hlth, CA, US; ⁵Chiang Mai Univ, Thailand; ⁶Desmond Tutu HIV Fndn, Cape Town, South Africa; ⁷Federal Univ of Rio de Janeiro, Brazil; and ⁸Gladstone Inst of Virology and Immunology, San Francisco, CA, US
11:00 am 95LB	Adherence Indicators and PrEP Drug Levels in the iPrEx Study Rivet Amico*¹, A Liu², V McMahan³, P Anderson⁴, J Lama⁵, J Guanira⁵, J-H Zheng⁴, D Glidden⁶, and R Grant³ ¹Univ of Connecticut, Storrs, US; ²San Francisco Dept of Publ Hlth, CA, US; ³Gladstone Inst of Virology and Immunology, San Francisco, CA, US; ⁴Univ of Colorado Denver, Aurora, US; ⁵Investigaciones Medicas en Salud, Lima, Peru; and ⁶Univ of California, San Francisco, US
11:15 am 96LB	Interpreting Detection Rates of Intracellular FTC-TP and TFV-DP: The iPrEx Trial Peter Anderson*¹, J Lama², S Buchbinder³, J Guanira⁴, O Montoya⁵, M Casapia⁶, L Bragg⁷, L Bushman¹, D Glidden⁸, R Grant^7,8, and iPrEx Study Team ¹Univ of Colorado Denver, Aurora, US; ²Investigaciones Medicas en Salud, Lima, Peru; ³San Francisco Dept of Publ Hlth, CA, US; ⁴Assn Civil Impacta Salud y Ed, Lima, Peru; ⁵Fndn Ecuatoriana Equidad, Guayaquil-Guayas, Ecuador; ⁶Assn Civil Selva Amazonica, Iquitos, Maynas, Peru; ⁷Gladstone Inst of Virology and Immunology, San Francisco, CA, US; and ⁸Univ of California, San Francisco, US
11:30 am 97LB	Drug Resistance and Minor Drug Resistant Variants in iPrEx Teri Liegler*¹, M Abdel-Mohsen¹, R Atchison², M Mehotra², T Schmidt¹, C Eden², D Glidden¹, S Buchbinder^1,3, J Lama⁴, R Grant^1,2, and iPrEx Study Team ¹Univ of California, San Francisco, US; ²Gladstone Inst of Virology and Immunology, San Francisco, CA, US; ³San Francisco Dept of Publ Hlth, CA, US; and ⁴Investigaciones Medicas en Salud, Lima, Peru
11:45 am 98LB	Predicting the Impact of ART and PrEP with Overlapping Regimens on HIV Transmission and Drug Resistance in South Africa Ume Abbas*¹, R Glaubius¹, A Mubayi¹, G Hood², and J Mellors³ ¹Cleveland Clin Fndn, OH, US; ²Pittsburgh Supercomputing Ctr, PA, US; and ³Univ of Pittsburgh, PA, US
12:00 pm 99LB	ART or PrEP for HIV Prevention in HIV Serodiscordant Partnerships: A Mathematical Modeling Comparison Timothy Hallett*¹, J Baeten², R Heffron², G De Bruyn³, S Delany-Moretlwe³, G Gray³, L Johnson⁴, J McIntyre³, H Rees³, and C Celum² ¹Imperial Coll London, UK; ²Univ of Washington, Seattle, US; ³Univ of the Witwatersrand, Johannesburg, South Africa; and ⁴Univ of Cape Town, South Africa